A synthetic heparin oligosaccharide decouples anticoagulation from heparin-induced thrombocytopenia risk.

Dodecasaccharide 12G-2 decouples anticoagulation from heparin-induced thrombocytopenia risk by preserving antithrombin binding while reducing PF4 binding and HIT antibody recognition.

• Why it matters: LMWH is limited by HIT risk and animal-derived supply constraints, creating a need for a synthetic heparin-like option that maintains anticoagulant function without triggering platelet activation.
• What they did: The team chemoenzymatically synthesized homogeneous 12G-2 with dual structural modulation, then tested anti-Factor Xa activity, venous and arterial antithrombotic efficacy, PF4 binding, β-sheet formation, antibody recognition, and platelet activation in vitro and in murine thrombosis and tail-bleeding models.
• The result: 12G-2 showed nanomolar anti-FXa activity, enoxaparin-equivalent venous efficacy, superior arterial antithrombotic activity, diminished PF4 binding and pathological β-sheet formation, high protamine reversibility, and reduced platelet activation in HIT-mimicking antibody–positive mice.

AI summary of the abstract · may contain errors · not medical advice · read the paper.